No drug-drug interaction after switch from ticagrelor to cangrelor in stable CAD

CHICAGO — Cangrelor infusion in adults with CAD pretreated with ticagrelor was associated with enhanced platelet inhibition compared with placebo, with no observed drug-drug interactions in the cangrelor group, researchers reported.“We know the current label for the use of cangrelor is for patients who have not been pretreated with an oral P2Y12 inhibitor,” Dominick J.

Related Keywords

United States ,Chicago ,Illinois ,American ,Dominickj Angiolillo ,Plx Pharma ,Daiichi Sankyo ,Eli Lilly ,Byregina Schaffer ,Erik Swain ,Amgen ,Uf Health Cardiovascular Center ,Boehringer Ingelheim ,American Heart Association Scientific Sessions ,Novartis ,Scottr Mackenzie Foundation ,Pfizer ,Astrazeneca ,Matsutani Chemical Industry Co ,Bristol Myers Squibb ,University Of Florida College Medicine ,Cardiovascular Center ,Florida College ,Switching Antiplatelet ,Total Thrombus Formation Analysis System ,